Alternatively spliced androgen receptor variants - Wikidata - wikimedia - TriplyDB

Alternatively spliced androgen receptor variants

Alternatively spliced androgen receptor variants

http://www.wikidata.org/entity/Q35606969

about

Splice Variants of Androgen Receptor and Prostate Cancer Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer Aberrant Lipid Metabolism Promotes Prostate Cancer: Role in Cell Survival under Hypoxia and Extracellular Vesicles Biogenesis Molecular signaling involving intrinsically disordered proteins in prostate cancer Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer Clonal origin and spread of metastatic prostate cancer Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Targeting molecular resistance in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression Targeting the adaptive molecular landscape of castration-resistant prostate cancer The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.Androgen receptor splice variants and prostate cancer: From bench to bedside.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?Inhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival.Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.A genome-wide analysis of open chromatin in human epididymis epithelial cells reveals candidate regulatory elements for genes coordinating epididymal function.The role of mRNA splicing in prostate cancer.JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation.Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis CYP3A5 regulates prostate cancer cell growth by facilitating nuclear translocation of AR.A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.Constitutive activity of the androgen receptor.GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer.Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.Structural basis for regulation of RNA-binding proteins by phosphorylation.MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand Alternative splicing of the androgen receptor in polycystic ovary syndrome.Age- and Sex-Dependent Changes in Androgen Receptor Expression in the Developing Mouse Cortex and Hippocampus Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding

P2860

Q26740592-D66548D5-3EAF-4723-BE4A-4F8A8734A9B0 Q26742062-5EA53653-1AA1-4E5D-B06F-49A0C83D8EE8 Q26744233-62C4D831-2A68-4430-B2A8-64307E069393 Q26747089-99AD8074-07EC-4046-BF28-60D9F46FEA66 Q26750620-AB595701-057A-4693-9CEF-9C2F3E6D3130 Q26752873-A969BD30-2735-4006-806C-802B3694C429 Q26774221-BD2920F5-2CB4-402B-B562-3B4613DAA99F Q26795445-790B8E36-693B-4F64-9CB7-E743052343A3 Q26796704-0FCC7D3A-9C1B-43CE-AE02-AAE2837D6AB8 Q27022288-5781C5CD-2002-4F02-9410-74019AC770F6 Q27022821-6B2672B7-E963-48D5-88F4-6374461B0831 Q28083838-B36C6466-212C-49A1-A11D-C0D08066DF00 Q28829239-9FB8074B-B2E4-4BF0-81BA-1D5E87743FE7 Q30544584-2869B5F3-403F-40C9-A304-FFFA59997F86 Q30554439-28AA9335-E5C3-4366-A7EF-41AF26504EA2 Q30831010-F52395A7-B2FF-4D8D-BB9D-230CEE85CB9D Q33567024-BFFCC067-6B83-45CB-A509-2A2CDBC1AFA0 Q33621403-652C1956-4643-4E89-88A5-AFD39B62E018 Q33688960-64F7AE06-0083-4E40-9EF1-B1DBCCF07C8F Q33775717-5BFABCB9-8701-4F6E-8EC1-A045B5C9C97C Q33780482-B7F519DB-5B35-491D-8084-C6A51AFA8BCA Q33821011-234321AC-6228-4C11-8FE7-4BB2F616698B Q33826288-55CE6E8E-14A4-4475-ABCB-349E7D47E1AD Q33922376-535A3944-A984-47AE-82F0-810D31F45921 Q34214362-E6C6AD28-8058-42EC-8413-9C77F74E6CA8 Q34289536-B6A4977B-156E-4383-A102-6F78EAF5C3F5 Q34364815-3D52BD57-C281-4213-B1A8-D77A30A3BA4E Q34428508-70641254-F5AE-4E35-AC57-A2C6EAD00A2D Q34458070-8ED23827-3C4D-4140-9D44-C119D773CE1A Q34550256-01170D51-9947-4C74-8416-125D33CBE612 Q34734595-FA9A6CC8-EF6A-4338-8B11-61B0F2C963B5 Q34775572-C09A0637-CF6F-4BC6-A36B-2469E7DDB6CC Q34793424-9313B77E-6132-4207-A51A-4453DEFF2D92 Q34883636-B86CF528-BC27-4D5F-BB81-9BD0C5479F78 Q35181646-E3DB2A99-5E65-44CB-92D1-18CFA9895F6D Q35213072-9577F880-E7BC-44B3-9246-B3F27A2A8E8B Q35238452-807C0265-D62D-4221-86FE-67D07FE02FE5 Q35484754-D6C8A4A6-06DD-4D47-880F-7E4A7EBDB6B3 Q35623225-3AFEBC59-F6AD-4A8B-8507-74DF7547B7E6 Q35624046-CC04D34F-0F6C-4FCC-85E1-4B3920F595B9

P2860

Alternatively spliced androgen receptor variants

http://www.wikidata.org/entity/Q35606969

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Alternatively spliced androgen receptor variants

@ast

Alternatively spliced androgen receptor variants

@en

type

label

Alternatively spliced androgen receptor variants

@ast

Alternatively spliced androgen receptor variants

@en

prefLabel

Alternatively spliced androgen receptor variants

@ast

Alternatively spliced androgen receptor variants

@en

P1433

Q35606969-32DD7690-91D8-4599-A79F-50751A56C9D1

P1476

Q35606969-36FFA320-D035-46ED-B6F6-8B5D50BE8204

P2093

Q35606969-245B77CA-897B-41FF-9BA2-96B739DC7A6C

Q35606969-2CA9C5CA-FAB3-4C06-AEE8-138329907BFC

P2860

Q35606969-08BA37A7-033B-43BF-B13B-F6A9CB37D3AB

Q35606969-0BBBA0D2-1695-470E-B4BF-D7D97F6BBB0B

Q35606969-0C66FCEA-0ED4-4BB2-9140-A426B9409A89

Q35606969-0FDF8EE0-4B57-4616-8AA1-8E1146502C8C

Q35606969-25065F9D-465E-4C99-B7BB-28963859CE3D

Q35606969-25A3619E-51AD-4BFF-98E1-F771B7F59AE4

Q35606969-2729DBE2-3356-4D70-9645-CF820EA37E63

Q35606969-3597232A-A2A0-44AC-A5F6-96759FF03FE4

Q35606969-366572F9-DD9B-4DCB-881A-5C75A32311F3

Q35606969-38BEA6A1-25C4-465E-8C47-F8CB13A3D5F4

P304

Q35606969-EE7B7F91-6098-4BF0-B7B2-A1FF33C38709

P31

Q35606969-ECC04B7F-9EB5-4031-945B-3D7B3B2CD75D

P356

Q35606969-7F32D392-C88F-4967-B877-7A37E0EF4546

P433

Q35606969-E9FE6889-FE0B-44D1-B61C-CA1F759FABD2

P478

Q35606969-0151A476-B85B-4793-AA6E-F1C903D3B4BC

P577

Q35606969-62524A03-9BA6-475C-A368-1F6C86EF3263

P698

Q35606969-8904BE65-A82D-4F18-95B9-D6172E261F51

P932

Q35606969-3322E156-9A8F-4CED-B4D4-1CA88016A479

P356

P1433

Endocrine-related cancer

P1476

Alternatively spliced androgen receptor variants

@en

P2093

Donald J Tindall

http://www.w3.org/2001/XMLSchema#string

Scott M Dehm

http://www.w3.org/2001/XMLSchema#string

P2860

The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Recognition and accommodation at the androgen receptor coactivator binding interface

Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations

Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone

Structural basis for the nuclear import of the human androgen receptor

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Androgen receptor in prostate cancer

P304

R183-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/ERC-11-0141

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21778211

http://www.w3.org/2001/XMLSchema#string

P932

3235645

http://www.w3.org/2001/XMLSchema#string